Polyoxazoline Drug Carriers for Hypersensitivity and Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug delivery systems, such as PEGylation, face challenges including hypersensitivity, antibody formation, limited drug loading, toxicity, and difficulties in orthogonal functionalization and storage of polyethylene glycol (PEG), while polyoxazoline polymers with pendant amine groups suffer from poorly defined polymers and toxic biodegradation.
Innovation Solution
Development of functionalized poly(2-oxazoline) polymers with repeating units that incorporate a hydrophilic amide group, allowing for orthogonal functionalization, improved solubility, and biodegradability, enabling the formation of conjugates with therapeutic, targeting, and diagnostic moieties for enhanced drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PEGylation is used to improve drug solubility and extend circulating half-life, then pharmacokinetic properties are improved, but hypersensitivity and antibody formation occur
Solution Approach 1:
The patent changes the chemical parameters of the polymer carrier by replacing PEG with polyoxazoline polymers having different compositions (varying ratios of formula I and II repeating units), molecular weights, and functional groups. This parameter change maintains the hydrophilic character and extended half-life benefits while eliminating the immunogenicity associated with PEG.
2Duration of action of moving object
If PEG with high molecular weight is used to extend circulating half-life, then pharmacokinetic properties are improved, but accumulation in the liver occurs leading to macromolecular syndrome
Solution Approach 1:
The patent optimizes the molecular weight parameters of the polyoxazoline polymer within a specific range (5,000 to 500,000 Da) and controls the composition ratio of repeating units to achieve the desired pharmacokinetic profile without liver accumulation, thereby extending half-life while avoiding macromolecular syndrome.
3Reliability
If PEG is used for drug conjugation, then solubility and stability are improved, but only low drug loading can be achieved due to limited hydroxyl terminal groups
Solution Approach 1:
The patent segments the polymer structure by incorporating multiple types of repeating units (formula I and II) with different functional groups distributed throughout the polymer chain. This segmentation creates numerous available sites for drug conjugation along the entire polymer backbone, not just at terminal groups, thereby significantly increasing drug loading capacity while maintaining stability.
Solution Approach 2:
The polyoxazoline polymer is designed with multiple functional groups (carboxylic acid, amine, hydroxyl, and other reactive groups) that can serve various functions: some for drug conjugation, others for stabilization, and additional ones for controlled release. This multi-functionality allows the same polymer structure to achieve both high drug loading and sustained stability.
4Quantity of substance
If PEG is used for drug delivery, then solubility is improved, but orthogonal functionalization with therapeutic, detection, or targeting moieties is not readily possible
Solution Approach 1:
The patent incorporates multiple types of functional groups within the same polyoxazoline polymer structure, each capable of different chemical reactions and interactions. This includes groups for covalent drug attachment, groups for non-covalent binding of targeting moieties, and groups for detection functionalities, enabling orthogonal functionalization while maintaining the hydrophilic solubility characteristics.
5Adaptability or versatility
If polyoxazoline polymers with pendant amine groups are used, then functionalization is improved, but poorly defined polymers and toxic biodegradation occur
Solution Approach 1:
The patent modifies the chemical structure by replacing pendant amine groups with carboxylic acid groups in the repeating units. This parameter change maintains the functionalization capabilities and hydrophilic character while eliminating the toxic biodegradation products associated with amine-containing polyoxazolines, resulting in well-defined polymer structures with controlled degradation profiles.
Data Source
AI summary
The present invention relates to functionalized ploy(2-oxazoline) polymers, which are very suitable as a carrier and/or delivery vehicle (conjugate) of drugs, such as small therapeutic molecules and bio-pharmaceuticals. These polymers are characterized in that they comprise repeating units that are represented by the following formula -[N(R1)-(CHR2)m]- wherein R1is R3-(CHR4)n-CONH-R5; R2is selectd from H and optionally substituted C1-5alkyl; R3is CH2CO, C(O)O, C(O)NH OR C(S)NH; R4is selected from H and optionally substituted C1-5alkyl; R5is H; an C1-5alkyl; aryl; or a moiety comprising a functional group that can be used for conjugation; m is 2 or 3 and n is 1-5; or n is 0 and R3is CH2. The invention relates further to a conjugate of these polyoxazoline polymers with at least one active moiety, such as a therapeutic moiety, a targeting moiety and/or diagnostic moiety, and to the use of these conjugates in the therapeutic treatment or prophylactic treatment or diagnosis of a disease or disorder.